BACKGROUND:Radiotherapy may lead to side effects that undermine patients' quality of life (QOL). Although mind-body practices like qigong appear to improve QOL in cancer survivors, little is known about their benefits for patients who are receiving radiotherapy. Thus, in the current randomized controlled trial, the authors examined the efficacy of a qigong intervention on QOL in women with breast cancer during and after treatment. METHODS:Ninety-six women with breast cancer were recruited from a cancer center in Shanghai, China, and were randomized to a qigong group (N = 49) or a waitlist control group (N = 47). Women in the qigong group attended 5 weekly classes over 5 or 6 weeks of radiotherapy. QOL outcomes (ie, depressive symptoms, fatigue, sleep disturbance, and overall QOL) and cortisol slopes were assessed at baseline, during treatment, at the end of treatment, 1 month later, and 3 months later. RESULTS:The mean age of the women was 46 years (range, 25-64 years). Seven percent of women had stage 0 disease, 25% had stage I disease, 40% had stage II disease, and 28% had stage III disease. Fifty-four percent of women underwent mastectomy. Multilevel analyses revealed that women in the qigong group reported less depressive symptoms over time than women in the control group (P = .05). Women who had elevated depressive symptoms at the start of radiotherapy reported less fatigue (P < .01) and better overall QOL (P < .05) in the qigong group compared with the control group, and these findings were clinically significant. No significant differences were observed for sleep disturbance or cortisol slopes. CONCLUSIONS: The current results indicated that qigong may have therapeutic effects in the management of QOL among women who are receiving radiotherapy for breast cancer. Benefits were particularly evident for patients who had preintervention elevated levels of depressive symptoms.
RCT Entities:
BACKGROUND: Radiotherapy may lead to side effects that undermine patients' quality of life (QOL). Although mind-body practices like qigong appear to improve QOL in cancer survivors, little is known about their benefits for patients who are receiving radiotherapy. Thus, in the current randomized controlled trial, the authors examined the efficacy of a qigong intervention on QOL in women with breast cancer during and after treatment. METHODS: Ninety-six women with breast cancer were recruited from a cancer center in Shanghai, China, and were randomized to a qigong group (N = 49) or a waitlist control group (N = 47). Women in the qigong group attended 5 weekly classes over 5 or 6 weeks of radiotherapy. QOL outcomes (ie, depressive symptoms, fatigue, sleep disturbance, and overall QOL) and cortisol slopes were assessed at baseline, during treatment, at the end of treatment, 1 month later, and 3 months later. RESULTS: The mean age of the women was 46 years (range, 25-64 years). Seven percent of women had stage 0 disease, 25% had stage I disease, 40% had stage II disease, and 28% had stage III disease. Fifty-four percent of women underwent mastectomy. Multilevel analyses revealed that women in the qigong group reported less depressive symptoms over time than women in the control group (P = .05). Women who had elevated depressive symptoms at the start of radiotherapy reported less fatigue (P < .01) and better overall QOL (P < .05) in the qigong group compared with the control group, and these findings were clinically significant. No significant differences were observed for sleep disturbance or cortisol slopes. CONCLUSIONS: The current results indicated that qigong may have therapeutic effects in the management of QOL among women who are receiving radiotherapy for breast cancer. Benefits were particularly evident for patients who had preintervention elevated levels of depressive symptoms.
Authors: N K Aaronson; B E Meyerowitz; M Bard; J R Bloom; F I Fawzy; M Feldstein; D Fink; J C Holland; J E Johnson; J T Lowman Journal: Cancer Date: 1991-02-01 Impact factor: 6.860
Authors: Kavita D Chandwani; Bob Thornton; George H Perkins; Banu Arun; N V Raghuram; H R Nagendra; Qi Wei; Lorenzo Cohen Journal: J Soc Integr Oncol Date: 2010
Authors: J C Pruessner; O T Wolf; D H Hellhammer; A Buske-Kirschbaum; K von Auer; S Jobst; F Kaspers; C Kirschbaum Journal: Life Sci Date: 1997 Impact factor: 5.037
Authors: M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: David Cella; Martin J Zagari; Christina Vandoros; Dennis D Gagnon; Hans-Jürgen Hurtz; Johan W R Nortier Journal: J Clin Oncol Date: 2003-01-15 Impact factor: 44.544
Authors: Rebecca A Campo; Neeraj Agarwal; Paul C LaStayo; Kathleen O'Connor; Lisa Pappas; Kenneth M Boucher; Jerry Gardner; Sierra Smith; Kathleen C Light; Anita Y Kinney Journal: J Cancer Surviv Date: 2013-10-30 Impact factor: 4.442
Authors: Linda K Larkey; Denise J Roe; Karen L Weihs; Roger Jahnke; Ana Maria Lopez; Carol E Rogers; Byeongsang Oh; Jose Guillen-Rodriguez Journal: Ann Behav Med Date: 2015-04
Authors: Heather Greenlee; Lynda G Balneaves; Linda E Carlson; Misha Cohen; Gary Deng; Dawn Hershman; Matthew Mumber; Jane Perlmutter; Dugald Seely; Ananda Sen; Suzanna M Zick; Debu Tripathy Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Peter M Wayne; M S Lee; J Novakowski; K Osypiuk; J Ligibel; L E Carlson; R Song Journal: J Cancer Surviv Date: 2017-12-08 Impact factor: 4.442
Authors: B L Vanderbyl; M J Mayer; C Nash; A T Tran; T Windholz; T Swanson; G Kasymjanova; R T Jagoe Journal: Support Care Cancer Date: 2017-01-19 Impact factor: 3.603
Authors: Heather Greenlee; Melissa J DuPont-Reyes; Lynda G Balneaves; Linda E Carlson; Misha R Cohen; Gary Deng; Jillian A Johnson; Matthew Mumber; Dugald Seely; Suzanna M Zick; Lindsay M Boyce; Debu Tripathy Journal: CA Cancer J Clin Date: 2017-04-24 Impact factor: 508.702